Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Minisymposium Presentation at AACR
April 08, 2021 18:00 ET | Cancer Advances Inc
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that its abstract...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Abstract at AACR
March 23, 2021 08:00 ET | Cancer Advances Inc
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Poster Presentation at ASCO GI
January 21, 2020 22:20 ET | Cancer Advances Inc
DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology
November 11, 2019 03:00 ET | Cancer Advances Inc
Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. PAS vaccine...
Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy
November 11, 2019 02:00 ET | Cancer Advances Inc
Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy.Polyclonal Antibody Stimulator...